When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in ...

US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase ...

This was the stock's second consecutive day of gains.

Aug 7 (Reuters) - Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals (VRTX.O), opens new tab and CRISPR Therapeutics (CRSP.BN), opens new tab ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue of $2.77 billion, up 3% year over year. In addition, Vertex revealed ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A ... US, UK, EU, and Australia), and that these figures will continue to trend in a similar ...

Read here for a discussion of Vertex Pharmaceuticals' (VRTX) strong Q2 results, potential for long-term growth, and valuation concerns in the market.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ... On March 7, 2025, the company received approval from the UK’s Medicines ...